Notable antiproliferation properties against breast cancer cell lines (MTT method, IC50 = 2.92, 1.08, 4.56 μM against MCF7 “wild p53”, MDA-MB-231 “mutant p53”, and MCF 10A, respectively) were reported for the synthesized conjugate 105 with X = (CH2)2 (Supplementary Figure S18). Here, TP53 is linked to breast carcinoma.